Patient Global Impression of Severity Data
For your patients with 4-14 MHDs per month,
Patients reported a significantly greater reduction in the severity of their disease with Emgality, on average, over Months 4 to 6 (p=0.002)1,4
- EVOLVE-1: Mean change from baseline in PGI-S score was -1.59 for Emgality vs -1.27 for placebo. LS mean difference: -0.32 (p=0.002)a
- EVOLVE-2: Mean change from baseline in PGI-S score was -1.22 for Emgality vs -0.94 for placebo. LS mean difference: -0.29 (p=0.002)a
Mean change from baseline in the PGI-S score over Months 4 to 6.4
aEVOLVE-1: Emgality 120 mg (N=189), placebo (N=377); EVOLVE-2: Emgality 120 mg (N=213), placebo (N=396).